Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
JMP Securities Reiterates Market Outperform Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:09 PM EDTJMP Securities analyst Jason N. Butler reiterated a Market Outperform rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "Solid ZTALMY growth as we look to key Phase 3 TSC results by mid-4Q24; we reiterate our Market Outperform rating and $10 risk-adjusted,... More
Truist Securities Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:04 PM EDTTruist Securities analyst Joon Lee reiterated a Buy rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "2Q24: Ph3 TrustTSC trial remain on track for topline in late Oct/early Nov. Low discontinuation rate of... More
